Short Communication: High Natural Polymorphism in the gag Gene Cleavage Sites of non-B HIV Type 1 Isolates from Gabon

Abstract

The main goal of the present study was to determine the frequency of substitutions in the cleavage sites (CS) of gag gene among non-B HIV-1 isolates from Gabon. Fifty plasma specimens, collected in 2010–2011, from HIV-1-infected patients failing first-line antiretroviral (ARV) regimens (constituted of two nucleoside reverse transcriptase inhibitors+one nonnucleoside reverse transcriptase inhibitor) (n=38) and from HIV-1-infected individuals untreated with ARV (n=12) were analyzed in the gag and gag-pol cleavage sites. Compared to HXB2 reference sequence, the total median number of substitutions in gag and gag-pol CS was 10 (range, 5–18). The cleavage site p2/NC was the most variable of the four gag CS with 100% (50/50) isolates carrying at least 1 substitution (range, 1–9). The two gag-pol TFP/p6^pol and p6^pol/PR CS sites were also highly variable (at least one substitution, 50/50, 100% in both cases). Substitutions at position G381 (p2/NC), L449 (p1/p6^gag), and K444 (TFP/p6^pol) were significantly more frequent in CRF02_AG strains, compared to other non-B strains (30.4% vs. 3.7%, p=0.03; 87.0% vs. 59.3%, p=0.03; and 91.3% vs. 59.3%, p=0.01, respectively). Other non-B subtypes were significantly more likely to harbor substitutions at position N487 (p6^pol) (70.4%) than CRF02_AG (39.1%) (p=0.02). In Gabon, gag and gag-pol cleavage sites were highly polymorphic in protease inhibitor-naive patients harboring non-B HIV-1 strains. In sub-Saharan Africa, further studies are definitively required to better understand the impact of gag mutations among subjects receiving second-line LPV/r-containing regimens (monotherapy or triple combinations).

Get full access to this article

View all access options for this article.

References

World Health Organization: Towards universal access: Scaling up the priority HIV/AIDS interventions in the health sector. World Health Organization: Geneva, 2010. www.who.int/hiv/pub/2010progressreport/summary_en.pdf.

Liegeois

, Vella

, Eymard-Duvernay

et al. Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. J Int AIDS Soc, 2012; 15:17985.

Murphy

, Sunpath

, Lu

et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS, 2010; 24:1007–1012.

Wallis

, Mellors

, Venter

et al. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat, 2011; 2011:769627.

Dlamini

, Hu

, Ledwaba

et al. Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir- or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr, 2011; 58:304–308.

Bartlett

, Ribaudo

, Wallis

et al. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS, 2012; 26:1345–1354.

Zhang

, Imamichi

et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol, 1997; 71:6662–6670.

Nijhuis

, van Maarseveen

, Lastere

et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med, 2007; 4:e36.

Gupta

, Kohli

, McCormick

et al. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS, 2010; 24:1651–1655.

10.

Fun

, Wensing

, Verheyen

et al. Human immunodeficiency virus gag and protease: Partners in resistance. Retrovirology, 2012; 9:63.

11.

Ghosn

, Delaugerre

, Flandre

et al. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS One, 2011; 6:e24798.

12.

Vergne

, Diagbouga

, Kouanfack

et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther, 2006; 11:575–579.

13.

Pasquier

, Millot

, Njouom

et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods, 2001; 94:45–54.

14.

Vergne

, MalongaMouellet

, Mistoul

et al. Resistance to antiretroviral treatment in Gabon: Need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr, 2002; 29:165–168.

15.

Bally

, Martinez

, Peters

et al. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses, 2000; 16:1209–1213.

16.

Kolli

, Stawiski

, Chappey

et al. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol, 2009; 83:11027–11042.

17.

Larrouy

, Chazallon

, Landman

et al. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients. Antimicrob Agents Chemother, 2010; 54:2910–2919.

18.

Firnhaber

, Azzoni

, Foulkes

et al. Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One, 2011; 6:e21450.

19.

Lockman

, Hughes

, Sawe

et al. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: A randomized trial. PLoS Med, 2012; 9:e1001236.

20.

Murphy

, Sunpath

, Castilla

et al. Second-line antiretroviral therapy: Long-term outcomes in South Africa. J Acquir Immune Defic Syndr, 2012; 61:158–163.

21.

Sigaloff

, Hamers

, Wallis

et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: Prospective cohort in Sub-Saharan Africa. J Infect Dis, 2012; 205:1739–1744.

22.

Levison

, Orrell

, Gallien

et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One, 2012; 7:e32144.